Latest News for CAMRF
PDUFA target action date set to 18 December 2026 LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA)…
Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript
Wall Street has pushed to next year expectations for a U.S. approval for Camurus' drug to treat a rare hormonal condition after the health regulator's second refusal on Wednesday.
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's exclusive, global rights to Camurus' FluidCrystal® technology for the development and commercialization of long acting…
Camurus AB (publ) (CAMRF) Q1 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CAMRF.
Senate Trading
No Senate trades found for CAMRF.
U.S. House Trading
No House trades found for CAMRF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.